This gene-editing therapy is engineered to enter liver cells using two different biological pathways, which may allow it to work even in people whose LDL receptors are impaired due to their genetic condition.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether dual-pathway delivery systems (LDLR + ASGPR) achieve higher hepatocyte editing efficiency and LDL-C reduction in patients with HeFH compared to single-pathway systems.
A systematic review and meta-analysis of all preclinical and clinical studies comparing hepatocyte delivery efficiency and PCSK9 editing rates in HeFH patients using GalNAc-LNP, LDLR-targeted, or dual-targeted systems, with outcomes measured by sequencing and LDL-C reduction.
Whether VERVE-102 achieves higher PCSK9 editing efficiency in HeFH patients with confirmed LDLR mutations compared to a single-pathway control therapy.
A double-blind RCT of 80 adults with HeFH and confirmed LDLR loss-of-function mutations, randomized 1:1 to VERVE-102 (dual-pathway) or a GalNAc-LNP without LDLR targeting, measuring on-target editing efficiency in liver biopsies and LDL-C reduction at 12 weeks.
Whether patients with HeFH and low LDLR activity show greater PCSK9 editing and LDL-C reduction after VERVE-102 than those with normal LDLR function.
A prospective cohort study of 120 HeFH patients stratified by LDLR functional status (via genetic testing and receptor binding assays), receiving VERVE-102, with primary outcome of PCSK9 editing efficiency and LDL-C reduction at 24 weeks.
Whether patients with poor response to VERVE-102 have lower ASGPR expression or LDLR activity compared to responders.
A nested case-control study within a phase 2 cohort comparing 20 non-responders (LDL-C reduction <20%) to 40 responders (LDL-C reduction >40%) after VERVE-102, measuring hepatic ASGPR and LDLR expression via biopsy and serum biomarkers.
Whether individuals with rare LDLR or ASGPR variants show unexpected responses to VERVE-102 delivery.
Detailed reporting of 5–10 individuals with HeFH and rare LDLR or ASGPR variants who received VERVE-102, including pre-treatment receptor expression levels, editing efficiency, and lipid response.